期刊文献+

雄附散阻抗大鼠肺间质纤维化的病理形态观察 被引量:2

Pathollmorphological study on Xiongfusan's attenuation of bleomycin-induced pulmonary fibrosis in rats
暂未订购
导出
摘要 目的通过观察肺间质纤维化模型大鼠肺组织的病理形态学变化,探讨雄附散对肺间质纤维化的疗效和早期使用中药干预肺纤维化的意义。方法将70只SD大鼠随机分为正常组、假手术组、模型组、醋酸泼尼松组(5.6mg/kg)、雄附散高、中、低剂量组(1.4、0.7、0.35g/kg)。各组大鼠于造模后的第2天开始连续4周灌胃给予生理盐水(0.014L/kg)或相应药物(0.014L/kg),28d后取右中肺组织进行HE染色和Masson染色及电镜观察。结果 HE染色和Masson染色均提示雄附散高剂量组肺组织无明显纤维化病变,电镜超微结构亦显示雄附散高剂量组肺组织与正常对照组相似。结论高剂量雄附散可有效对抗博来霉素致大鼠肺间质纤维化模型的纤维化过程。 Objective To study the effect of Xiongfusan on attenuation of bleomycin-induced pulmonary fibrosis and the value of early-stage intervention by Chinese traditional medicine by observing the pulmonary morphological changes in the model rats. Methods Seventy SD rats were randomly divided into 7 groups(10 rats each),i.e.blank control group,pseudosurgical group,model group,prednisone group(5.6mg/kg),and three Xiongfusan groups(1.4,0.7,0.35 g/kg).Normal saline(0.014 L/kg)and drugs (0.014 L/kg)were administered separately at D_4 post-bleomycin instillation by daily gastrogavage for 4 weeks.The morphologic characteristics (HE stain,Masson stain and ultrastructure)were observed after 28 days treatment.Results No obvious morphologic changes were observed in the high dose Xiongfusan group by histopathologic evaluation,HE staining,Masson staining,or the transmission electron microscopy.Conclusions Xiongfusan may attenuate bleomycin-induced pulmonary fibrosis effectively.
出处 《武警医学》 CAS 2010年第2期131-134,共5页 Medical Journal of the Chinese People's Armed Police Force
基金 "十一五"军队中医药重大临床攻关课题(2006011003)
关键词 雄附散 肺纤维化 形态病变 超微结构 Xiongfusan pulmonary fibrosis morphological changes ultrastructure
  • 相关文献

参考文献11

  • 1杨永滨,王勇,马玉琛,董超,耿朝晖,肖锋.雄附散抑制大鼠肺间质纤维化过程中肺组织iNOS的表达水平[J].医学研究与教育,2009,26(6):1-3. 被引量:2
  • 2王勇,马玉琛.痰毒并治类风湿性关节炎致肺间质纤维化[J].中国中医急症,2009,18(3):395-396. 被引量:12
  • 3周刚,牛建昭,王继峰,陈伟涛,刘同祥,李银生,李泽华.姜黄素抗肺纤维化大鼠自由基损伤作用的实验研究[J].中国中药杂志,2006,31(8):669-672. 被引量:39
  • 4R. Demir,H. Bodur,F. Toko?lu,I. Olcay,H. U?an,P. Borman.High resolution computed tomography of the lungs in patients with rheumatoid arthritis[J]. Rheumatology International . 1999 (1-2)
  • 5Aho K,Heliovaara M.Risk factor for rheumatoid arthritis. Annals of Medicine . 2000
  • 6Dawson J K,,Fewins H E,Desmond J,et al.Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography,chest radio-graphy,and pulmonary function tests. Thorax . 2001
  • 7Moeller A,Askc K,Warburton D,et al.The bleomycin animal model:A useful tool to investigate treatment options for idiopathic pulmonary fibrosis. International Journal of Biochemistry Cell Biology The . 2008
  • 8Sriram N,Kalayarasan S,Sudhandiran G.Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates,lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis. Chemico Biological Interactions . 2009
  • 9Goodson N,,Marks J,Lunt M,et al.Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Annals of the Rheumatic Diseases . 2005
  • 10Oku H,Shimizu T,Kawabata T,et al.Antifibrotic action of pirfenidone and prednisolone:different effects on pulmo-nary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. European Journal of Pharmacology . 2008

二级参考文献27

共引文献49

同被引文献20

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部